Mobilization of peripheral blood progenitor cells following CHOP treatment combined with delayed granulocyte colony-stimulating factor administration in patients with non-Hodgkin's lymphoma

Leukemia & Lymphoma
H TakanoT Koike

Abstract

The kinetic change in peripheral blood progenitor cells (PBPC) during 3 to 6 cycles of standard CHOP regimen supported with human recombinant granulocyte colony-stimulating factor (rG-CSF) was investigated in three patients with newly diagnosed intermediate grade, diffuse large cell type, non-Hodgkin's lymphoma (NHL) without bone marrow invasion. Patients were given rG-CSF subcutaneously (2 mu g/kg/day) initiated when total leukocytes was < 3.0 x 10(9)/1. When the leukocyte count remained at >3.0 x 10(9)/1, rG-CSF was started 10 days following the prior CHOP. Treatment with rG-CSF was discontinued after the leukocyte count reached >10.0 x 10(9)/1, and CHOP was started the next day (CHOP-G regimen). The number of PBPC was monitored by clonal assay in patients 1-3. No severe leukopenia with <0.5 x 10(9)/1 of neutrophils was seen in any patient. Colony-forming unit granulocyte-macrophage (CFU-GM) significantly increased after 2-3 days of consecutive administration of rG-CSF. The magnitudes of maximum amplification of CFU-GM in patients 1, 2, and 3, were 56-fold (during 3 cycles of CHOP-G), 216-fold (during 2 cycles), and 67-fold (during 4 cycles), respectively, and the absolute numbers of the maximum CFU-GM/ml blood were 983, 7,56...Continue Reading

References

Mar 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·B J Clarke, D Housman
Jan 1, 1992·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·H DemuynckN G Testa
Jun 1, 1990·Journal of Clinical Ultrasound : JCU·W H ChowA S Yip
Jul 1, 1985·Annals of Internal Medicine·M Coleman
May 1, 1985·Annals of Internal Medicine·P Klimo, J M Connors
Aug 16, 1986·Lancet·L B ToC A Juttner
Sep 1, 1987·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F R AppelbaumJ E Sanders
Oct 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M VoseJ O Armitage
Dec 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A P RapoportM A Tanner

❮ Previous
Next ❯

Citations

Jul 10, 1999·Journal of Chromatography. a·J W Cochran, G M Frame
Jul 27, 2001·Mathematical Biosciences·E K Afenya
Dec 10, 1999·Critical Reviews in Oncology/hematology·G LeoneL Pagano
Nov 24, 2004·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Kazuma IkedaMine Harada
Feb 1, 2014·ChemMedChem·Huan-Huan ZhengYu-Lin Li
Oct 14, 2005·Journal of Medicinal Chemistry·Richard Morphy, Zoran Rankovic

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.